GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa

2nd Annual Gene Therapy for ophthalmic Disorders, digital event

5th Annual Cell & Gene Therapy World Asia, virtual

Clinical Trials in Rare Diseases Conference 2021, Europe and USA, virtual conference

GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects before LUMEVOQ® treatment in Phase III Trials

Ophthalmology Futures Forums – Euro Retina Virtual Forum, September 8, 2021

UK MHRA grants GenSight Biologics’ LUMEVOQ® ophthalmic gene therapy Promising Innovative Medicine designation

2021 ISGEDR Meeting (International Society for Genetic Eye Diseases & Retinoblastoma)

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September

GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®